We are developing platforms to screen the medicines of tomorrow for side effects and provide patients with safer and better treatments.

Overview

The most effective medicine is useless if its side effects are overlooked. There are over 100 drugs that have been withdrawn from the market because they have caused heart attacks, strokes, dangerous irregular heartbeats, or even death.

We share a vision where medications are both effective and safe and where the safety of patients can be guaranteed through rigorous toxicity compound screening.

Human stem cell technology allows for this vision to become reality. By assembling technology that was developed in a world-leading academic laboratory, we are poised to develop the world’s first platform to detect drug side effects caused in different parts of the human cardiovascular system.

Our iPSC platform

Induced pluripotent stem cell (iPSC) technology has become a cornerstone in modeling human diseases due to its unique ability to differentiate into diverse cellular subtypes. Traditional animal models often struggle to replicate the intricacies of human diseases, particularly neurodegenerative conditions that involve selective neurodegeneration in the human brain. These limitations make it difficult to validate effective treatments for such diseases.

iPSC technology offers a powerful alternative, enabling:

• In-depth mechanistic studies to understand disease pathways.
• Large-scale drug screening campaigns to identify novel active compounds.
• Discovery and validation of therapeutic targets.

Wild-type human iPSC lines for research use only

We offer a selection of commercially consented, off-the-shelf, research-grade iPSC lines, cryopreserved in 1.2 mL threaded cryogenic vials with a 1 mL fill volume.

Key features of our iPSC lines:

• Quality-controlled for pluripotency and trilineage differentiation markers.
• Comprehensive SNP-based array karyotyping to confirm genetic stability.
• Tested for human pathogens, sterility, and mycoplasma.
• STR analysis to confirm identity and genetic integrity.
• Verified post-thaw viability to ensure performance.
• Provision of Ready-to-Differentiate Format (optional).

License-backed assurance

Through our license agreements with iPS Academia Japan, Inc., and ID Pharma, we are authorized to provide our high-quality iPSC lines and derived cardiovascular models to our clients, ensuring compliance and reliability for research and development purposes.

This integrated approach enables us to deliver trusted tools and solutions that empower groundbreaking discoveries in the field of drug development and disease modeling.

hiPSC
human induced pluripotent stem cells

Custom-made & ready-to-order

Trusted service

ABS Biotechnologies has a world-leading team of experienced and passionate stem cell biologists. We have previously set up and operated the world's largest stem cell pipeline in Cambridge, UK and have performed cutting edge stem cell science over the past two decades. We know your needs!

Our manufacturing process

Why choose ABSB hiPSC?

• World-leading expertise in hiPSC manufacturing.
• Reliable, high-quality and tailored hiPSCs.
• Ethnically diverse and footprint-free clones.
• Lead time of 4 months for customised lines.

What we offer

ABS Biotechnologies generates high-quality hiPSC lines from whole blood and skin biopsy samples from carefully screened and consented donors.

All generated hiPSC lines undergo meticulous quality control, including genetic integrity testing, cell line authentication, proof of pluripotency marker expression and differentiation into the three germ layers.

1. Whole blood

• Derived from peripheral blood mononuclear cells (PBMC).
• Obtained through centrifugation of whole blood, erythroblast expansion and reprogramming.

2. Skin biopsy

• Derived from skin fibroblasts.
• Obtained through skin biopsy, fibroblast expansion and reprogramming.

• Ready-to-order whole blood-derived hiPSC lines.
• Custom-made hiPSC lines: whole blood or skin biopsy-derived.

Our drug screening platform

ABS Biotechnologies’ drug screening platform offers solutions for drug developers that current compound screening technology can not address.

1. Blood vessel cells from diverse anatomic locations:
ABS Biotechnology is capable of generating blood vessel cells corresponding to different anatomic locations in the human body. For the first time, this allows for detection of side effects that occur only in certain vascular beds of the human body, including heart attacks and strokes.

2. High-maturity cardiomyocytes:
A better understanding of heart development has allowed us to generate heart tissue that more closely resembles mature human heart tissue. The use of our patented epicardial cell technology gives rise to high-fidelity heart muscle cells that can predict dangerous irregular heartbeats with greater precision than existing technologies.